Scribe clears first human trial for cholesterol CRISPR

Australian regulators clear Scribe Therapeutics to begin testing a one-time CRISPR therapy designed to lower “bad” cholesterol for years. Cardiovascular disease remains the world’s biggest killer, yet one of its main drivers – elevated LDL cholesterol – is often treated with therapies people must ta…